Evidence map›Paper›PMID 35811971›Full record

ArticleFrontiers in nutrition2022

Ho-Young Park, Hye-Bin Lee, So-Young Lee, Mi-Jin Oh, Sang Keun Ha, Eunju Do, Hyun Hee L Lee, Jinyoung Hur, Kwang-Won Lee, Mi-Hyun Nam and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Metabolites fromACS omega · 2023
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Ho-Young ParkFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
Hye-Bin LeeFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
So-Young LeeFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
Mi-Jin OhFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
Sang Keun HaFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
Eunju DoClinical Trial Convergence Commercialization Team, Daegu Technopark, Daegu, South Korea.
Hyun Hee L LeeFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
Jinyoung HurFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
Kwang-Won LeeDepartment of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, South Korea.
Mi-Hyun NamDepartment of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado, Aurora, Aurora, CO, United States.
Myoung Gyu ParkMetaCenTherapeutics, Suwon, South Korea.
Yoonsook KimFood Functionality Research Division, Korea Food Research Institute, Jeollabuk-do, South Korea.
Korea Food Research Institute · KRDaegu TechnoPark · KRKorea University · KRUniversity of Colorado Anschutz Medical Campus · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Excessive intake of advanced glycation end products (AGEs), which are formed in foods cooked at high temperatures for long periods of time, has negative health effects, such as inflammatory responses and oxidative stress. N Materials and Methods: We investigated the effect of treatment with Results: Administration of LL-KF140 reduced serum CML levels and hepatic CML absorption in rats that were fed a CML-enriched product. In a human trial, the intake of LL-KF140 prevented increases in the serum levels of CML and alanine aminotransferase after consumption of a CML-rich cheese. LL-KF140 was determined to presence in feces through metagenome analysis. Furthermore, β-galactosidase, one of the

Indexed as

advanced glycation end product (AGE)Lactococcus lactis (L. lactis)Nε-(carboxymethyl)lysine (CML)probioticβ-galactosidase

Identifiers

PMID35811971
PMCPMC9263842
OpenAlexW4283361246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.